A phase 1 trial found that personalized neoantigen vaccines combined with PD-1 blockade were feasible in high-grade serous ovarian cancer and produced tumor-specific immune responses in many patients, with resistance mechanisms linked to antigen presentation identified through c…
Personalized Neoantigen Vaccines Show Feasibility in Ovarian Cancer Trial
A phase 1 trial found that personalized neoantigen vaccines combined with PD-1 blockade were feasible in high-grade serous ovarian cancer and produced tumor-specific immune responses in many patients, with resistance mechanisms linked to antigen presentation identified through cell-free DNA analysis.
![[Correspondence] Unmasking inequity: emergency presentations in ovarian cancer care – Authors’ reply](https://nbg1.your-objectstorage.com/ckln/image-assets/1479f6e02a47e83f65a2418f624184c37083a97e4bf59e158c428bf07c0ae2e9.jpg)
Ovarian cancer · Wikimedia — licence per file · rights
This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.
Monitoring item. The full text is not distributed. Extract and source below.